Answers are grounded in this paper and cite their sources.
Objective: : Systematic literature searches used predefined search terms in PubMed, Ovid Embase, Ovid MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials. Databases were searched from inception to August 2024. Study eligibility criteria: Interventional and observational studies comparing pregnancy outcomes amongst women with a pre- or early-pregnancy (<20 weeks' gestation) BMI ≥30 kg/m² according to presence or amount of any antenatally measured biomarker were included. Study appraisal and synthesis methods: Two reviewers independently assessed studies for inclusion against predefined inclusion and exclusion criteria. Risk of bias assessment was performed on included studies using the Newcastle-Ottawa Risk of Bias Tool. A narrative synthesis of eligible studies was constructed and data were meta-analysed, where possible, using random effects models. Certainty of evidence was assessed by GRADE rating. Results: 0%). Certainty of evidence regarding all associations was low or very low. Conclusions: Decreased adiponectin and increased insulin are associated with increased risk of adverse pregnancy outcomes in women with BMI ≥30 kg/m². However, the low number of studies available for inclusion and low certainty of evidence mean that biomarker-based risk-stratification within pregnant women with BMI ≥30 kg/m² is not currently feasible. Further research is required to find ways of reliably targeting investigations during maternity care towards the subset of women living with obesity who are at highest risk of adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Wishlade et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: